Prism Pharmaceuticals Inc. of King of Prussia announced today that it will receive a $10 million milestone payment from Paul Capital Healthcare, triggered by Monday's U.S. Food and Drug Administration approval of the new drug application for Nexterone, a formulation of the antiarrhythmic agent Amiodarone IV.
